Several reports point to hyperactivation of PI3K signaling in AML, and activated AKT is commonly associated with poor overall survival of patients with AML as well as with a less complete response (CR) rate to chemotherapy (18–23). This evidence concerns the gene PIK3CD and acute myeloid leukemia.